Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/54—Biologically active materials, e.g. therapeutic substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/02—Inorganic materials
  • A61L27/04—Metals or alloys
  • A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/58—Materials at least partially resorbable by the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/02—Inorganic materials
  • A61L31/022—Metals or alloys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L31/148—Materials at least partially resorbable by the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L31/16—Biologically active materials, e.g. therapeutic substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
  • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L31/18—Materials at least partially X-ray or laser opaque
• • C—CHEMISTRY; METALLURGY
  • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
  • C22C—ALLOYS
  • C22C1/00—Making non-ferrous alloys
• • C—CHEMISTRY; METALLURGY
  • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
  • C22C—ALLOYS
  • C22C23/00—Alloys based on magnesium
• • C—CHEMISTRY; METALLURGY
  • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
  • C22F—CHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
  • C22F1/00—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
  • C22F1/06—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of magnesium or alloys based thereon
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
  • A61F2/89—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2002/828—Means for connecting a plurality of stents allowing flexibility of the whole structure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
  • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
  • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
  • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
  • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
  • A61F2250/0071—Additional features; Implant or prostheses properties not otherwise provided for breakable or frangible
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
  • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
  • A61F2250/0096—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
  • A61F2250/0098—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers

Definitions

• This application relates generally to implants, and more specifically to bioabsorbable intraluminal implants.
• Drug eluting stents cut the retreatment rate again significantly by addressing the SMC proliferation with a pharmaceutical agent, but again was accompanied by a "new" complication, late stent thrombosis (LST) and the accompanying extended use of anti-coagulants.
• LST late stent thrombosis
• LST is associated with high mortality rates, although the frequency of the events is relatively low. The apparent factors driving this serious complication appear to he the loss of vaso- motion and delayed healing of a functional endothelium.
• One such implant application is absorbable metal stents for vascular or luminal scaffolding, such as stents for treatment of coronary artery disease.
• the stents provide a temporary scaffolding through the healing process related to the local injury caused by the high pressure angioplasty balloon used to open the stenosed or partially blocked artery.
• the metal scaffold is typically required only for a period of days to weeks to prevent abrupt closure of the vessel from spasm, minimize elastic recoil, and as a substrate to deliver a controlled release drug-polymer formulation to the site of injury. After this period, any remnant of the alloy or its degradants may be a liability, since it can act as a foreign body prolonging an inflammatory response and delaying healing.
• An alternative design approach towards absorbable stents utilizes highly crystalline absorbable polymers such as PLLA for the structural elements of the stent scaffold. This approach has a more controlled degradation process, but suffers from low radial stiffness that is needed to open the artery, i.e., so called acute gain, and limited ductility making stent-artery sizing problematic.
• a permanent implant known as a drug eluting stent or DES.
• the DES is a third generation angioplasty device for treating coronary stenosis, with significantly lower re -intervention rates than either bare metal stents or balloon angioplasty.
• This generation technology is a permanent implant, typically comprising a high strength and high radiopacity metal such as cobalt chrome or platinum enriched stainless steel, coated with a formulation of an anti-proliferative drug in a controlled release polymer.
• L-poly lactic acid (pLLA) and magnesium alloys are both essentially radio-transparent, small disc-shaped radio-markers comprised of platinum, platinum-iridium, or tantalum are typically integrated into the end of the laser cut stent body. If there are 2 or 3 radio-markers on each end of the stent, then the location and level of deployment can be visualized by angiography during a procedure, even if the bulk of the stent is not radio-opaque. This is a well established approach for nickel-titanium permanent stents which possessed low intrinsic radio-opacity.
• embodiments of the invention address the deficiencies of conventional polycrystalline metal-based alloys of magnesium, iron, zinc, calcium, and manganese for elongated implants through control of the microstructure to yield either single crystal or columnar crystal structures that extend continuously for the length of the implant or implant sub-component.
• This structure yields a more controlled and uniform strength retention and degradation profile than conventional polycrystalline structures, which rapidly lose strength due to corrosion along grain boundaries but then have long absorption times due to the slow corrosion rate of the bulk of the alloy within the individual grains.
• the implants of this invention lose strength and mass in parallel as the cross-sectional area is reduced through surface erosion.
• cardiovascular implants are described; these implants are based on bioabsorbable stent scaffolds that may resolve both the vaso-motion and foreign body issues, by fully absorbing in a period of 3-24 months post-implantation.
• Embodiments of the invention address the deficiencies of previous absorbable intraluminal implants for local drug delivery by a composite design that utilizes absorbable metal and absorbable polymer technologies.
• the design includes a plurality of discrete rings or a continuous helix of ring-like structures formed of an absorbable metal, such as magnesium, zinc, or iron and their respective alloys, to achieve high radial force and stiffness necessary to prevent vessel recoil.
• the structural rings are not interconnected by metal elements, but instead by flexible absorbable polymer connectors with a different absorption time than the metal ring elements.
• the device serves as a drug delivery substrate by inclusion of an active pharmaceutical, preferably an anti-proliferative agent to smooth muscle cells that is eluted at a controlled rate over a period of weeks to months.
• Embodiments of the invention include a hybrid intraluminal implant that consists of a plurality of cylindrical or "ring" segments, with alternating segments of bioabsorbable and biostable
• the "end" segments include a biostable and radio-opaque material such as a cobalt chrome alloy or stainless steel, and at least one inner ring segment comprising or consisting essentially of bioabsorbable material such as magnesium or its alloys.
• the ring segments are connected by polymeric connectors to avoid uncontrolled galvanic reactions between the permanent and absorbable metals in the presence of physiological fluid containing chlorides (saline).
• the implant's utility is enhanced by incorporation of an anti-proliferative drug with sustained release.
• the acute performance of the hybrid stent is similar to conventional DES implants regarding acute luminal gain.
• the bioiabsorbable segments are fully absorbed in 6 months allowing endothelial healing and return of vaso-motion.
• the biostable ring segments are permanent radiomarkers that are self-sufficient for preventing migration and embolization.
• the biostable segments also provide load sharing to the adjacent absorbable metal segments through the polymer connectors, reducing lumen loss during the absorbable segment fragmentation period.
• embodiments of the invention include a bioabsorbable implant including an elongated metallic element having more than about 50% by weight the metal magnesium, iron, zinc, calcium, or manganese, and/or combinations or alloys thereof and being substantially free of rare earth metals, namely the 15 lanthanoid elements, i.e., the elements having a proton number of 57-71, scandium, and yttrium.
• the elongated metallic element may define at least a portion of the
• the metal may define a continuous single grain and/or a columnar microstructure.
• the metal may define a columnar microstructure including grains having an average grain length of at least about 1 mm, and an average grain diameter of less than about 0.2 mm.
• the average grain length may be at least about 10 mm and/or the average grain diameter may be less than about 3 mm.
• the continuous single grain may have an aspect ratio of grain length to grain diameter of at least 10: 1.
• the columnar microstructure may include grains having an aspect ratio of grain length to grain diameter of at least 10: 1.
• the elongated metallic element may a wire, rod, and/or a hollow tube.
• the wire may have a diameter of less than about 0.2 mm.
• the bioabsorbable implant may be an intraluminal device, a ligating clip, a ligating clip component, a bone fixation device (e.g., a plate, a pin, or a screw), or a bone-to-soft-tissue fixation device (e.g., a suture anchor, an interference screw, and a cross pin).
• a bone fixation device e.g., a plate, a pin, or a screw
• a bone-to-soft-tissue fixation device e.g., a suture anchor, an interference screw, and a cross pin.
• embodiments of the invention include a bioabsorbable implant including an elongated metallic element having more than about 50% by weight a metal and being substantially free of rare earth elements, the elongated metallic element defining at least a portion of the bioabsorbable implant and including a wire formed into a bioabsorbable continuous helical sinusoid.
• the metal may be magnesium, iron, zinc, calcium, or manganese and/or combinations or alloys thereof.
• the wire may define at least one of a continuous single grain and a columnar microstructure.
• embodiments of the invention include a bioabsorbable implant including an elongated metallic element having more than 50% by weight a metal and being substantially free of rare earth elements.
• the elongated metallic element may define at least a portion of the bioabsorbable implant and may include a wire formed into a first bioabsorbable expandable metal ring and a second bioabsorbable expandable metal ring.
• the bioabsorbable implant may also include at least one flexible longitudinal connecter including an absorbable polymer and connecting the first and second expandable metal rings.
• a coating including a pharmaceutically active agent may be disposed over at least a portion of at least one of the first and second metal rings and the longitudinal connector.
• the metal may be magnesium, iron, zinc, calcium, or manganese, and/or combinations or alloys thereof.
• At least one of the expandable metal rings comprises a wire may define a single grain and/or a columnar microstructure.
• At least one of the expandable metal rings may include a stud configured for coupling with an adjacent feature.
• the at least one flexible longitudinal connector may include a biodegradable
• homopolymer and/or a aliphatic polyester such as lactic acid, lactide, glycolic acid, glycolide, caprolactone, dioxanone, trimethylcarbonate, and co-polymers and blends thereof.
• the at least one flexible longitudinal connector may include directionally oriented absorbable filaments extending along a length of the bioabsorbable implant and/or extruded tubes of absorbable polymer. At least one of the expandable rings may form an aperture adapted for coupling with the at least one flexible longitudinal connector.
• the pharmaceutically active agent may include or consist essentially of, e.g., a potent anti-proliferative to human smooth muscle cells, taxane, an mTOR agent, and/or a chemoactive agent suitable for cancer treatment.
• a potent anti-proliferative to human smooth muscle cells e
• embodiments of the invention may include a bioabsorbable implant including an elongated metallic element having more than about 50% by weight a metal and being substantially free of rare earth elements.
• the elongated metallic element may define at least a portion of the bioabsorbable implant, and may include a wire formed into a discrete bioabsorbable expandable metal ring.
• the bioabsorbable implant may also include at least two biostable ring elements, each biostable ring including a biostable and radio-opaque metallic alloy, with the bioabsorbable expandable metal ring being disposed adjacent at least one of the biostable rings.
• At least one flexible longitudinal connecter including a bioabsorbable polymer may be disposed between at least two adjacent rings.
• a coating including at least one pharmaceutically active agent may be disposed over at least a portion of one ring.
• the metal may be magnesium, iron, zinc, calcium, or manganese, and/or combinations or alloys thereof.
• At least two of the biostable rings may include a laser-machined hypo-tube made of, e.g., cobalt, chrome, stainless steel, titanium, or iron and/or alloys thereof.
• At least one of the discrete biostable rings may define an aperture and/or a stud configured to couple with the at least one flexible longitudinal connector.
• the at least one flexible longitudinal connector may include a biodegradable homopolymer and/or a aliphatic polyester, e.g., lactic acid, lactide, glycolic acid, glycolide, caprolactone, dioxanone, trimethylcarbonate, and co-polymers and blends thereof.
• the at least one flexible longitudinal connector may include directionally oriented absorbable filaments extending along a length of the bioabsorbable implant and/or extruded tubes of absorbable polymer.
• the pharmaceutically active agent may include or consist essentially of a potent antiproliferative to human smooth muscle cells, taxane, an mTOR agent, and/or a chemoactive agent suitable for cancer treatment.
• Figure 1 is a schematic diagram of a segment of an elongated implant or sub-component such as a wire or pin with a conventional poly crystalline grain structure;
• Figure 2 is a schematic diagram of a segment of an elongated implant or sub-component processed by directional solidification that yields a plurality of columnar crystals in accordance with an embodiment of the invention
• Figure 3 is a schematic diagram of an elongated implant or sub-component formed of a single crystal that is essentially without grain boundaries in accordance with an embodiment of the invention
• Figure 4 is a schematic diagram of a segment of directionally solidified alloy formed into a sub-component of an implant, in accordance with an embodiment of the invention.
• Figure 5 is a schematic diagram of a segment of directionally solidified alloy formed into a ligating clip, in accordance with an embodiment of the invention.
• Figure 6 is a schematic diagram of directionally solidified alloy formed into a bone fixation device, in accordance with an embodiment of the invention.
• Figure 7 is a schematic diagram of a segment of directionally solidified alloy blank formed into a bone anchor, in accordance with an embodiment of the invention.
• Figure 8 a is a schematic diagram of a wire formed into a continuous sinusoidal-like wave form in accordance with an embodiment of the invention.
• Figure 8b is a schematic diagram illustrating the continuous sinusoidal-like wave form of
• Figure 8a being wrapped around a mandrel, in accordance with an embodiment of the invention
• Figure 8c is a schematic diagram of a bioabsorbable continuous helical sinusoid, in accordance with an embodiment of the invention.
• Figure 9 is a schematic diagram of a single expandable ring made of an absorbable magnesium alloy wire that has been mechanically formed and welded in accordance with an embodiment of the invention.
• Figure 10 is a schematic diagram of a plurality of expandable metal rings connected by discrete loops of absorbable polymer in accordance with an embodiment of the invention
• Figure 11 is a schematic diagram of a plurality of expandable metal rings connected longitudinally by interwoven filaments made of absorbable polymer, with connectors extending continuously the full length of the implant in accordance with an embodiment of the invention
• Figure 12a is a schematic diagram of segments of expandable metal rings with stud features and a small diameter extruded tube of flexible absorbable polymer cut to length in accordance with an embodiment of the invention
• Figure 12b is a schematic diagram of an assembled composite implant with the tube connecting the stud features on adjacent segments in accordance with an embodiment of the invention
• Figure 13 is a longitudinal cross sectional view of a plurality of expandable metal rings connected by injection-molded longitudinal connectors of flexible absorbable polymer in accordance with an embodiment of the invention
• Figure 14 is a longitudinal cross-sectional view of a 3-layer sandwich construction of braided absorbable polymer filaments on outer and inner layers, encapsulating a middle layer of expandable metal rings in accordance with an embodiment of the invention
• Figure 15 is a schematic diagram of a hybrid stent including thin ring segments made from a biostable and radio-opaque material, a larger center ring segment made from an absorbable magnesium alloy, and filament connectors between segments made of absorbable polymer in accordance with an embodiment of the invention;
• Figure 16 is a schematic diagram of eyelet design features that facilitate the interlacing of ring segments by continuous filament connectors in accordance with an embodiment of the invention.
• Figure 17 is a schematic diagram of a hybrid stent with a plurality of alternating biostable and absorbable ring segments and absorbable polymer connectors in accordance with an embodiment of the invention.
• a segment of an elongated implant 100 or sub-component such as a wire or pin with a conventional polycrystalline grain structure in cross-section A-A has a plurality of grains 110 separated by grain boundaries 120.
• Grain boundaries 120' that are aligned perpendicularly to the primary loading axis may be initiation points for premature failure due to accelerated corrosion or crack formation from fatigue.
• the crystal structure in accordance with embodiments of the invention may be either single crystal (i.e., a continuous single grain) or columnar crystal structures (i.e., a columnar microstructure) that extend continuously for the length of the implant or implant sub-component.
• a bioabsorbable implant may include an elongated metallic element or subcomponent that may be formed by directional solidification that yields a columnar microstructure 200 plurality of columnar crystals 210 that extend essentially the full functional length of the implant 100.
• a single crystal structure 220 that is essentially without grain boundaries is shown for clarity, with dimensions of z » x, z»y.
• the columnar microstructure may include grains having an average grain length of preferably at least about 1 mm, and an average grain diameter of preferably less than about 0.1 mm.
• the average grain length may be at least about 10 mm.
• the average grain diameter is at least about 5 mm.
• the metal may include one or more grains having an aspect ratio of grain length to diameter of at least 10: 1, preferably 100: 1 or more.
• the implant or implant sub-component may be processed from a melt by a process that controls the direction of solidification along its elongated axis. This may achieved through controlled heat removal (under-cooling) at one end of the elongated structure so that crystal nucleation and propagation is driven down its length (z axis in Figure 2), while crystal formation in the directions perpendicular to elongated axis are retarded by keeping those surfaces at an elevated temperature with insufficient under-cooling for nucleation. Additional mechanical forming processes can be practiced following directional solidification to achieve the final implant geometry, if the thermal treatments do not result in a re-crystallization that reverts the structure to polycrystalline.
• a suitable process for forming at least a portion of an implant from a melt is the Ohno process.
• the Ohno process typically used to form copper wires, is described in the literature. See, e.g.:
• the Ohno process is a continuous casting process that uses a heated mold, rather than a cooled mold.
• the mold is heated slightly above the melting point of the metal to be solidified. This has the result that no new grains can nucleate at the mold wall. Solidification is restricted to the contact area between the melt and the dummy rod or single crystal seed, which is withdrawn from the melt.
• the mold can be positioned either vertically upward, vertically downward, or horizontal. The melt stays in the mold even when the mold is not positioned vertically upward, as the die diameter is small, and grips or pinch rollers are needed to pull the wire out of the mold.
• An advantage of the Ohno process is that it can be used for directional solidification or crystal growth, and ingots or crystals of unlimited length may be produced.
• the resulting material has a smooth surface and inner quality due to the fact that impurities are moved to the boundaries, resulting in a pure crystal.
• superior mechanical properties are achieved due to the resulting directionally solidified microstructure.
• One way to create a wire using the Ohno process is to utilize a crucible furnace with a melt level control, a heated mold with a small diameter channel, a cooling device to cool the wire after it exits the mold, and pinch rolls to pull the wire away from the mold.
• Wire/bar drawing a metalworking process known to those of skill in the art, allows for successive reductions in diameter of the bar/wire by pulling the wire/bar through successively smaller diameter dies.
• the successive reductions in diameter result in expansion of the length of the wire.
• the die is typically mounted on a draw bench and the end of the wire is placed in grips so that the rest of the wire may be pulled through the die.
• the process of drawing improves the mechanical properties of the wire due to work hardening.
• eutectic Mg-Al wires of 5 mm in diameter with mirror-smooth surface may be continuously solidified with a casting speed 10 mm/min, a mold exit temperature of 450°C, a static pressure head of the melt of 5 mm, a flow rate of cooling water 30 L/h, and a mold- cooling water distance 20 mm. Under these casting conditions, the wires solidify just outside of the mold exit.
• an elongated metallic element may include more than about 50% by weight a metal, such as magnesium, iron, zinc, calcium, and/or manganese metals and/or combinations or alloys thereof, and is preferably substantially free of rare earth metals.
• substantially free of rare earth metals means that less than 0.1% (by weight) of the metallic alloys includes rare earth metals. Anything less than 0.1% is in the hundreds parts per million range, which is below the FDA threshold in safety profiles of individual impurities in drugs. At that level, rare earth metals also do not have a significant effect on corrosion properties.
• the metallic alloy may be at least 80% Mg, with the balance including the elements Ca, Mn, Zn, Fe, plus trace elements. It may be preferable to use pure Mg as a basis for the alloy, with no inclusion of rare earth metals.
• a segment of an elongated implant or subcomponent processed by directional solidification yields a single columnar crystal 300 that extends essentially the full functional length of the implant.
• the elongated metallic element may define at least a portion of the bioabsorbable implant.
• the elongated metallic element may include a wire.
• the wire may have a diameter of less than about 0.2 mm.
• diameters above about 0.2 mm may create too much trauma to the vessel wall.
• diameters up to several mm may be preferred.
• the elongated metallic element may include a wire formed into at least one discrete bioabsorbable expandable metal ring, or a wire formed into a bioabsorbable continuous helical sinusoid.
• the metal ring may be formed from welded wire forms or by laser micro- machining of metal tubing.
• the bioabsorbable implant may be any one of various devices, such as an intraluminal device.
• a segment of directionally solidified alloy may be formed into a subcomponent of an implant, i.e., a ring element 400 of a balloon expandable coronary stent 410.
• the bioabsorbable implant may also be a ligating clip or a ligating clip component.
• a segment of directionally solidified alloy may be formed into a ligating clip 500 for tubular anatomical structures.
• the bioabsorbable implant is a bone fixation device 600 for fracture fixation, e.g., a plate 610, a pin, or a screw 620.
• the bioabsorbable implant is a bone -to-soft-tissue fixation device, e.g., a suture anchor, an interference screw, or a cross pin.
• a segment of directionally solidified formed alloy, produced as discussed above, in the form of a blank 700 may be formed into a bone anchor 710 (also referred to as a suture anchor) for soft tissue reattachment by means of a suture 720.
• a preferred embodiment of a bioabsorbable implant is a bioabsorbable helical continuous sinusoid.
• This structure may include a wire formed into the sinusoid; the wire may define either a continuous single grain or a columnar microstructure.
• a helical continuous sinusoid may be defined as a wire -form tubular structure made from a wire that is first formed into a continuous sinusoidal-like wave form 800, and that is secondly wrapped in a helical configuration around a cylindrical mandrel 810 to form a tubular but mechanically unstable structure.
• a pharmaceutically active agent may be disposed over at least a portion of the helical continuous sinusoid 840.
• the pharmaceutically active agent may be one of many suitable materials. For example, it may be a potent anti-proliferative to human smooth muscle cells, and a chemoactive agent suitable for cancer treatment.
• the agent may be a taxane, such as Paclitaxel, its derivatives and prodrugs thereof.
• the agent may be a known mTOR agent such as sirolimus or everolimus, their derivatives and prodrugs thereof.
• the implant may locally deliver both a taxane and a mTOR agent.
• the active agent may be eluted at a controlled rate through formulation with a biodegradable polymer.
• One key aspect of one design in accordance with an embodiment of the invention is a more controlled, graceful degradation process than that of existing fully absorbable metal stent designs.
• the integral metal longitudinal connecting elements degraded at a similar rate to the structural ring elements.
• long and wide stent fragments may be formed consisting of multiple ring fragments and intact metal connectors. The shape and size of these fragments make them problematic relative to obstructing the vessel lumen.
• the fragment size is reduced by using longitudinal connectors comprised of an absorbable polymer with significantly faster degradation kinetics than the metal rings.
• the high surface area and favorable surface chemistry of the polymeric longitudinal connectors contribute to rapid tissue coverage and integration of the implant into the vessel wall.
• a single discrete bioabsorbable expandable metal ring 900 may be made from a wire of an absorbable magnesium alloy wire that has been mechanically formed and welded.
• the ring 900 may also be formed from any of the other alloys discussed above, including iron, zinc, calcium, and/or manganese metals or alloys, or any other material suitable for forming a bioabsorbable implant.
• a plurality of expandable metal rings 900 formed from wire may be connected by discrete loops of absorbable polymer, i.e., flexible longitudinal connector 1000, and mounted on a balloon catheter 1010.
• the plurality of rings may include a first discrete bioabsorbable expandable metal ring and a second discrete bioabsorbable expandable metal ring, with at least one flexible longitudinal connecter, including an absorbable polymer, connecting the first and second discrete expandable metal rings.
• a coating including a pharmaceutically active agent may be disposed over at least a portion of at least one of the first and second metal rings and the longitudinal connector.
• At least one of the expandable metal rings may include a wire defining a single grain or a columnar microstructure.
• One or more of the flexible longitudinal connectors may include a biodegradable homopolymer of an aliphatic polyester, such as lactic acid, lactide, gly colic acid, glycolide, caprolactone, dioxanone, trimethylcarbonate, and co-polymers and blends thereof.
• a biodegradable homopolymer of an aliphatic polyester such as lactic acid, lactide, gly colic acid, glycolide, caprolactone, dioxanone, trimethylcarbonate, and co-polymers and blends thereof.
• the pharmaceutically active agent may be one of many suitable materials. For example, it may be a potent anti-proliferative to human smooth muscle cells, and a chemoactive agent suitable for cancer treatment.
• the agent may be a taxane, such as Paclitaxel, its derivatives and prodrugs thereof.
• the agent may be a known mTOR agent such as sirolimus or everolimus, their derivatives and prodrugs thereof.
• the implant may locally deliver both a taxane and a mTOR agent.
• the active agent may be eluted at a controlled rate through formulation with a biodegradable polymer.
• a plurality of expandable metal rings 900 or a helical continuous sinusoid may be connected longitudinally by interwoven filaments 1100 made of absorbable polymer.
• a longitudinal cross-sectional view shows the metallic rings 900 and interwoven filaments 1100.
• the helical continuous sinusoid 840 may also be similarly connected longitudinally by interwoven filaments 1100 (not shown).
• At least one of the flexible longitudinal connectors may include directionally oriented absorbable filaments extending along a length of the bioabsorbable implant.
• At least one of the expandable metal rings 900 may define a stud feature 1200.
• the stud is configured to allow for mechanical connection of adjacent ring segments.
• a hollow, small diameter extruded tube of, e.g., flexible absorbable polymer of PLGA may be cut to length 1210 and interference fit over the opposing stud features 1200 to form a longitudinal connector 1220.
• a plurality of expandable metal rings 900 or a helical continuous sinusoid 840 may be connected by injection-molded longitudinal connectors 1300 of flexible absorbable polymer.
• the flexible longitudinal connectors may include extruded tubes of absorbable polymer.
• a 3-layer sandwich construction may include braided absorbable polymer filaments on outer 1400 and inner layers 1410, encapsulating a middle layer of expandable metal rings 900.
• At least one of the expandable rings form an eyelet adapted for coupling with the at least one flexible longitudinal connector (see eyelet 5 in Figure 14).
• a hybrid stent may include thin proximal and distal ring segments
• a larger center ring segment 1510 including, e.g., a plurality of rings 900 made of a bioabsorbable magnesium alloy (or any or the other bioabsorbable alloys discussed herein) or a helical continuous sinusoid 840, and filament connectors, e.g., longitudinal connectors 1000 made of a bioabsorbable polymer such as PLGA.
• the bioabsorbable expandable metal ring 900 may be disposed adjacent at least one of the biostable rings 1500, 1500', and at least one flexible longitudinal connecter 1000 is disposed between at least two adjacent rings.
• a coating including at least one pharmaceutically active agent may be disposed over at least a portion of one ring.
• At least one of the biostable rings may be a laser-machined hypo-tube including cobalt, chrome, stainless steel, titanium, and/or iron.
• At least one of the flexible longitudinal connectors may include a biodegradable homopolymer and/or an aliphatic polyester such as lactic acid, lactide, glycolic acid, glycolide, caprolactone, dioxanone, trimethylcarbonate, and/or co-polymers and blends thereof.
• a biodegradable homopolymer and/or an aliphatic polyester such as lactic acid, lactide, glycolic acid, glycolide, caprolactone, dioxanone, trimethylcarbonate, and/or co-polymers and blends thereof.
• At least one of the flexible longitudinal connectors may include directionally oriented absorbable filaments extending along a length of the bioabsorbable implant and/or extruded tubes of absorbable polymer such as PLGA.
• the pharmaceutically active agent may be one of many suitable materials.
• it may be a potent anti-proliferative to human smooth muscle cells, and a chemoactive agent suitable for cancer treatment.
• the agent may be a taxane, such as Paclitaxel, its derivatives and prodrugs thereof.
• the agent may be a known mTOR agent such as sirolimus or everolimus, their derivatives and prodrugs thereof.
• the implant may locally deliver both a taxane and a mTOR agent.
• the active agent may be eluted at a controlled rate through formulation with a biodegradable polymer.
• At least one of the discrete biostable rings 1500, 1500' may define an eyelet 1600 and/or a stud configured to couple with at least one flexible longitudinal connector, e.g., interwoven filaments 1100.
• the eyelet design features 1600 facilitate the interlacing of the laser cut biostable proximal and distal ring segments 1500, 1500' by continuous filament connectors 1100 that transverse the center bioabsorbable segment 1510 including a plurality of bioabsorbable rings 900 or a helical continuous sinusoid 840.
• a hybrid stent may include a plurality of alternating biostable 1500 and bioabsorbable ring segments 1510 and bioabsorbable polymer connectors 1000.
• a 99.99% pure magnesium rod of 20 cm length and 5 mm diameter may be directionally solidified from the melt in an induction-heated graphite mold equipped with means for rapid cooling from a single end, e.g., the Easyheat 0112 system available from Ameritherm, based in ScottsviUe, New York.
• a center section of the rod may be mechanically reduced to a diameter of 1.5 mm, and the rod may then be drawn at an elevated temperature to a wire diameter of 125 microns.
• the wire may be cut to length, and bent on a wire forming machine into a sinusoidal geometry with a peak-to-valley height of 1.25 mm.
• a 6 crown ring may be formed by bending a cut length of the linear wire form around a circular mandrel, clamping it in place with opposing wire ends coming in direct contact and overlapped, followed by laser welding to form a lap joint.
• the metal stent rings may then be electro-polished to a final wire diameter of 120 microns while smoothing weld joints.
• a series of 12 rings may be welded together at 3 locations per ring to form a 15 mm long vascular stent.
• the stent platform may be spray coated with 200 microgram coating weight (dry) of D,L PL A -Paclitaxel with a 5% drug load, predominantly on the external or abluminal surface.
• the drug coated stent may be crimped on an angioplasty balloon catheter, and sterilized by e-beam sterilization.
• a metal including, e.g., 100% magnesium may be continuously cast by the Ohno continuous casting process used for preparing single crystal fine copper wire, and then drawn to a final diameter of 110 microns, with a length of several miles.
• the wire may be cut to length sufficient to define one discrete ring, and bent on a wire forming machine into a sinusoidal geometry with a peak to valley height of 1.0 mm.
• a 6 crown ring may be formed by bending a cut length of the linear wire form around a circular mandrel, clamping it in place with opposing wire ends coming in direct contact and overlapped, followed by laser welding to form a lap joint.
• the metal stent rings may then be electro- polished to a final wire diameter of 100 microns while smoothing weld joints. Then a stable and dense MgO layer of approximately 1 micron may be formed through electrochemical techniques to passivate the implant surface. A series of 15 rings may be interconnected with filaments of absorbable copolymer of 10%lactide-90% glycolide to form a vascular stent.
• the stent platform may be spray coated with 200 microgram coating weight (dry) of D,L PLA -Paclitaxel with a 7.5% drug load. The drug coated stent may be crimped on an angioplasty balloon catheter, and sterilized by ethylene oxide sterilization.
• a ligating clip may be made from 1.5 mm x 1.5 mm square stock a magnesium-based directionally solidified alloy.
• the square blank may be cast in a heated tool that is equipped for super cooling from one end, resulting in a microstructure of columnar grains extending for its entire length.
• the square blank may be cut to length, electro-polished, and then passivated with the formation of dense MgO layer.
• the blank may be formed into an open "V" clip by hot working to form the hinge point, and cold coining of the outer surfaces to form details for engagement and retention within the jaws of a clip applier.
• the cartridge of clips may be packaged and sterilized by conventional gamma sterilization at a minimum dose of 3.0 MRads.
• the clips may retain integrity for 4 weeks in vivo, and may be used for small vascular vessel ligation, or for reproductive sterilization.
• a bone fixation device may be made from a high purity alloy of 98%Mg-2%Ca that is directionally solidified into a 2.5 mm cylindrical blank, which is subsequently tapered in a secondary grinding process.
• the pin may then be electro-polished to remove surface contaminants and then treated by electrochemical means to form a dense magnesium oxide layer.
• the pin preferably possesses the necessary mechanical strength and ductility for an interference fit for insertion into a pre -drilled hole in two bone fragments.
• the pin preferably retains physical integrity and prevents micro-motion between the fragments for period of 12 weeks, and is subsequently fully absorbed.
• a directionally solidified wire of pure Mg with 10-90 PLGA filament longitudinal connectors and spray coated paclitaxel-PLA coating may be made as follows. High purity magnesium may be directionally solidified and drawn into a 125 micron diameter round wire. The wire may have an ultimate tensile strength of 125 MPa and elongation to break greater than 25%. The wire may be formed on a four slide wire forming machine into conventional sinusoidal or racetrack geometry with a ring height of 1.0 mm in the crimped state. A 6 crown ring may be formed by bending the linear wire form around a circular mandrel, clamping it place with opposing wire ends coming in direct contact and overlapped, followed by laser welding to form a lap joint. The metal stent rings may then
• Longitudinal connectors may be made from 10-90 PLGA, by taking 12 rings and lacing or weaving them together axially with 3 filament bundles, each equivalent to 5-0 Vicryl suture, and spaced at approximately 120 degrees apart around the ring circumference.
• the final composite assembly may be heat set at 60 °C to a final length of 15 mm.
• the assembly may be spray coated with 200 microgram coating weight (dry) of D,L PL A -Paclitaxel with a 5% drug load, predominantly on the external or abluminal surface.
• the drug-coated stent may be crimped on an angioplasty balloon catheter, and sterilized by e-beam sterilization.
• a magnesium alloy laser-cut ring with extruded tubular 5050 PLGA polymer longitudinal connectors and a coating of 8020 PLGA polymer with 10% paclitaxel may be made as follows.
• a magnesium alloy may be formed into a 2.0 mm (outside diameter) hypo-tube.
• the hypo-tube may be laser cut into ring segments, with 8 crowns per ring.
• Each ring segment may have at least 2 elongated stud features of 0.4 mm length and facing matching studs on an opposing ring.
• the rings may then be connected by flexible longitudinal connectors of 1.0 mm long tubular extrusions of 50-50 PLGA placed over each stud.
• rings with 13 sets of connectors may be assembled into a 20 mm stent, expandable to 3.0 mm diameter.
• the assembly may be spray coated with a 250 microgram coating weight (dry) of 8020 PLGA polymer pre -compounded with 10% (by weight) Paclitaxel drug.
• the drug coated stent may be crimped on an angioplasty balloon catheter and sterilized by e-beam.
• Hyper-fine grain, Mg-Ca alloy wire with Polydioxanone polymer longitudinal connectors and a D,L-PLA-Sirolimus Drug Coating may be made as follows. High purity magnesium- l%Ca with grain size below 5 microns may be drawn and annealed into a 100 micron wire. The wire may be formed into a 6 crown design and welded into a ring. Twelve rings may be equally spaced in a cavity of a steel mold, and poyldioxanone (PDO) in a solvent solution may be vacuum injected into the cavity. Following secondary processes for solvent removal and annealing, the structure may be 15 mm long with 12 metal ring segments. The assembly may be spray coated with 200 microgram coating weight (dry) comprised of 50% D,L PLA and 50% Sirolimus.
• dry microgram coating weight
• a Mg-alloy wire- PGA fiber braid with high load chemo-active agent was made as follows. An alloy of magnesium was melted and processed into 160 micron wire. The wire was formed into continuous sinusoid wave form and then wrapped in a helical geometry around a 4.0 mm cylindrical mandrel. The tubular helical structure rings were coupled by longitudinal polymer connectors of Vicryl 6-0 suture (available from Ethicon Inc. of Somerville NJ). The finished tubular stent-like implant was 12 mm long and was coated with 120 micrograms (dry weight) of a 95% PLA - 5% paclitaxel formulation with a manual pipette system. Following mounting on a balloon catheter and ethylene oxide sterilization, the device was used as a short term, luminal drug delivery platform for treatment of cancer of the esophagus.
• a 15 mm x 3.5 mm diameter coronary stent may include 3 cylindrical or ring segments connected by longitudinal absorbable polymer element s.
• the proximal and distal ring segment may be made from a 75 micron 316L stainless steel alloy wire that is formed into a sinusoidal waveform that is wrapped around a mandrel and welded to form a segment of 2.5 mm in length.
• the central ring segment may be formed from a Mg high purity alloy that is cast and drawn into a wire of 100 microns in diameter.
• the Mg wire may be formed on a multi-slide machine into a continuous sinusoidal waveform, wound on a mandrel, and laser welded at select connection points between subsequent rows of rings to form a segment of 8.0 mm in length.
• the three segments may be connected by interlacings of a 6-0 Vicryl absorbable PLGA suture, with an effective connector length of 0.5 mm each.
• the entire assembly may be coated with a formulation of approximately 6% Paclitaxel in 90-10 PLGA, crimped on an angioplasty catheter, packaged, and sterilized.
• a 20 mm x 3.5 mm diameter coronary stent may include 3 cylindrical or ring segments connected by longitudinal absorbable polymer elements.
• the proximal and distal ring segments may be made by laser cutting a cobalt chrome hypo tube into an open cell stent geometry followed by electro- polishing down to an 80 micron strut thickness.
• the effective length when expanded may be 4 mm, and the design may include eyelet features to facilitate interlacing with adjacent segments.
• the central segment may be made of mono-crystalline magnesium wire that is formed into a continuous sinusoidal waveform that is wrapped on a cylindrical mandrel and laser welded at given intervals to form a flexible segment 12 mm in length.
• the proximal, central and distal rings may be connected in a similar manner by interlacing with 6-0 PDO absorbable monofilament sutures to form an intraluminal implant of about 20 mm in length.
• the entire assembly may be coated with a 50-50 formulation of Sirolimus and DL- PLA with approximately 10 micrograms drug per stent mm in length.
• the stent assembly may be crimped on an angioplasty balloon catheter, packaged and sterilized.
• a 30 mm x 3.0 mm balloon expandable stent may be produced by means similar to the examples described as Example 10, with the exception of a third biostable segment at the center of the assembly.
• the stent may possess a proximal cobalt chrome laser cut segment of 4 mm, a magnesium wire form segment of 10 mm, a center cobalt chrome segment of 2 mm, another 10 mm magnesium segment, and the distal cobalt chrome ring segment of 4 mm, all interlaced together with 6-0 PDS absorbable monofilament suture.
• the entire assembly may be coated with a formulation of approximately 6% PT'x in 90-10 PLGA, crimped on an angioplasty catheter, packaged, and sterilized.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Vascular Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Surgery (AREA)
• Transplantation (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Biomedical Technology (AREA)
• Organic Chemistry (AREA)
• Materials Engineering (AREA)
• Mechanical Engineering (AREA)
• Metallurgy (AREA)
• Dermatology (AREA)
• Molecular Biology (AREA)
• Physics & Mathematics (AREA)
• Inorganic Chemistry (AREA)
• Crystallography & Structural Chemistry (AREA)
• Thermal Sciences (AREA)
• Optics & Photonics (AREA)
• Cardiology (AREA)
• Materials For Medical Uses (AREA)
• Prostheses (AREA)
• Media Introduction/Drainage Providing Device (AREA)

Priority Applications (4)

Applications Claiming Priority (6)

Publications (3)

Family

ID=45353276

Family Applications (1)

Country Status (6)

Cited By (4)

Families Citing this family (62)

Family Cites Families (149)

• 2011
  • 2011-06-21 EP EP11743676.6A patent/EP2582408B1/en not_active Not-in-force
  • 2011-06-21 CA CA2802753A patent/CA2802753C/en not_active Expired - Fee Related
  • 2011-06-21 WO PCT/US2011/041258 patent/WO2011163236A2/en not_active Ceased
  • 2011-06-21 US US13/165,247 patent/US8888841B2/en active Active
  • 2011-06-21 JP JP2013516690A patent/JP2013529507A/ja active Pending
  • 2011-06-21 ES ES11743676.6T patent/ES2522265T3/es active Active
• 2014
  • 2014-10-30 US US14/527,937 patent/US9849008B2/en active Active
• 2015
  • 2015-05-07 JP JP2015094696A patent/JP6470627B2/ja not_active Expired - Fee Related
• 2017
  • 2017-03-22 JP JP2017055441A patent/JP2017164502A/ja active Pending

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events